- Home
- GPATU vs DMAC Comparison
GPATU vs DMAC Comparison
Compare GPATU & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPATU
- DMAC
- Stock Information
- Founded
- GPATU N/A
- DMAC 2000
- Country
- GPATU
- DMAC United States
- Employees
- GPATU N/A
- DMAC N/A
- Industry
- GPATU
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- GPATU
- DMAC Health Care
- Exchange
- GPATU NYSE
- DMAC Nasdaq
- Market Cap
- GPATU N/A
- DMAC 158.1M
- IPO Year
- GPATU N/A
- DMAC N/A
- Fundamental
- Price
- GPATU $10.70
- DMAC $4.11
- Analyst Decision
- GPATU
- DMAC Strong Buy
- Analyst Count
- GPATU 0
- DMAC 2
- Target Price
- GPATU N/A
- DMAC $8.00
- AVG Volume (30 Days)
- GPATU N/A
- DMAC 102.4K
- Earning Date
- GPATU N/A
- DMAC 05-13-2025
- Dividend Yield
- GPATU N/A
- DMAC N/A
- EPS Growth
- GPATU N/A
- DMAC N/A
- EPS
- GPATU N/A
- DMAC N/A
- Revenue
- GPATU N/A
- DMAC N/A
- Revenue This Year
- GPATU N/A
- DMAC N/A
- Revenue Next Year
- GPATU N/A
- DMAC N/A
- P/E Ratio
- GPATU N/A
- DMAC N/A
- Revenue Growth
- GPATU N/A
- DMAC N/A
- 52 Week Low
- GPATU N/A
- DMAC $2.14
- 52 Week High
- GPATU N/A
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- GPATU N/A
- DMAC 50.90
- Support Level
- GPATU N/A
- DMAC $3.92
- Resistance Level
- GPATU N/A
- DMAC $4.33
- Average True Range (ATR)
- GPATU 0.00
- DMAC 0.29
- MACD
- GPATU 0.00
- DMAC 0.02
- Stochastic Oscillator
- GPATU 0.00
- DMAC 56.79
About GPATU GP-ACT III ACQUISITION CORP
GP-Act III Acquisition Corp is a blank check company.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.